Latest News

Liche Zhou, MD, of the department of neurology at Jiang University School of Medicine, provided commentary on new phase 1 data on an iPSC-targeted cell therapy presented at the 2025 MDS Congress.

New trial results reveal alixorexton's significant efficacy in treating narcolepsy type 2, marking a potential breakthrough in sleep medicine.

Findings from a second phase 3 trial, dubbed FENhance 1, assessing fenebrutinib in patients with relapsing multiple sclerosis are anticipated by the first half of 2026.

The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB provided clinical perspectives on the FDA approval of Kygevvi, the first marketed treatment specific for patients with thymidine kinase 2 deficiency (Tk2d).

Jupiter Neurosciences advances Parkinson treatment with FDA clearance for JOTROL's phase 2a trial, showcasing promising safety and bioavailability results.

Despite not meeting its primary efficacy end point for preventive treatment of episodic migraine, onabotulinumtoxinA was well tolerated and safety outcomes were consistent with prior data.

A genetic counselor-only clinic enhances access to genetic testing in pediatric neurology, proving efficient and effective for timely precision diagnostics.

Caregivers share insights on discussing social determinants of health in pediatric clinics, revealing preferences for surveys over in-person conversations.

A study reveals the intricate decision-making process caregivers face when considering gene therapy for Duchenne muscular dystrophy, emphasizing shared input and personal experiences.

Although their knowledge, experience, and access to genetic counselors varied, most licensed OB/GYNs across Ohio reported routinely offering carrier screening for spinal muscular atrophy.

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the 2025 AANEM Annual Meeting!

A study reveals that genetic counseling significantly empowers individuals at risk for frontotemporal dementia, highlighting the need for best practice guidelines.